Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 63% · stale
- Computed at
- 2026-07-23T19:13:14.150298+00:00
- Claimed
- 78
- Reported
- 78
- Verified
- 72
- Gap
- +6
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Growing
Decision
What the current evidence supports
Human editorial judgment · 2026-07-23
Adopt with guardrails
- Why
- FDA-approved (Jan 2025) with two positive Phase 3 RCTs and a genuine first-in-class non-opioid mechanism -- real, not speculative -- but incomplete payer coverage, premium-tier pricing friction, and 'comparable-not-superior-to-opioids' efficacy mean broad clinical/commercial guardrails (cost, indication scope, monitoring) are still warranted before treating it as a settled standard-of-care alternative.
- Next
- Re-check at the next H2 2026 refresh: track Phase 4 label expansion into chronic/neuropathic pain, PBM coverage crossing the 3-of-3 major-payer threshold, and whether real-world uptake data confirms non-opioid substitution (not just add-on use).
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 5
- Tier 1
- 0
- Tier 2
- 2
- Tier 3
- 3
- Supports
- 4
- Contradicts
- 1
- Context
- 0
- Latest observed
- 2025-08-05
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-07-23 Reading moved from ready to ready.